Overview

A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera

Status:
RECRUITING
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of 9MW3011 in Chinese patients with Polycythemia VeraPV.
Phase:
PHASE1
Details
Lead Sponsor:
Mabwell (Shanghai) Bioscience Co., Ltd.